



Age/Gender : 31 Y 11 M 2 D/M UHID/MR No : SCHI.0000018366

Visit ID : SCHIOPV38464

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 181659 Collected : 26/Oct/2024 10:52AM
Received : 26/Oct/2024 11:35AM
Reported : 26/Oct/2024 04:41PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

PERIPHERAL SMEAR, WHOLE BLOOD EDTA

Page 1 of 15







Age/Gender : 31 Y 11 M 2 D/M UHID/MR No : SCHI.0000018366

Visit ID : SCHIOPV38464

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 181659 Collected : 26/Oct/2024 10:52AM
Received : 26/Oct/2024 11:35AM
Reported : 26/Oct/2024 04:41PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
HEMOGRAM , WHOLE BLOOD EDTA				
HAEMOGLOBIN	13.8	g/dL	13-17	CYANIDE FREE COLOUROMETER
PCV	43.50	%	40-50	PULSE HEIGHT AVERAGE
RBC COUNT	5.37	Million/cu.mm	4.5-5.5	Electrical Impedence
MCV	80.9	fL	83-101	Calculated
MCH	25.6	pg	27-32	Calculated
MCHC	31.7	g/dL	31.5-34.5	Calculated
R.D.W	14.5	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	5,870	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUN	T (DLC)			
NEUTROPHILS	55.3	%	40-80	Electrical Impedance
LYMPHOCYTES	32	%	20-40	Electrical Impedance
EOSINOPHILS	3.9	%	1-6	Electrical Impedance
MONOCYTES	7.9	%	2-10	Electrical Impedance
BASOPHILS	0.9	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT				
NEUTROPHILS	3246.11	Cells/cu.mm	2000-7000	Calculated
LYMPHOCYTES	1878.4	Cells/cu.mm	1000-3000	Calculated
EOSINOPHILS	228.93	Cells/cu.mm	20-500	Calculated
MONOCYTES	463.73	Cells/cu.mm	200-1000	Calculated
BASOPHILS	52.83	Cells/cu.mm	0-100	Calculated
Neutrophil lymphocyte ratio (NLR)	1.73		0.78- 3.53	Calculated
PLATELET COUNT	242000	cells/cu.mm	150000-410000	IMPEDENCE/MICROSCOPY
ERYTHROCYTE SEDIMENTATION RATE (ESR)	10	mm at the end of 1 hour	0-15	Modified Westergren
PERIPHERAL SMEAR				

RBCs ARE NORMOCYTIC NORMOCHROMIC.

TLC , DLC WITHIN NORMAL LIMIT. NO IMMATURE CELLS ARE SEEN. PLATELETS ARE ADEQUATE.

Page 2 of 15







Age/Gender : 31 Y 11 M 2 D/M UHID/MR No : SCHI.0000018366

Visit ID : SCHIOPV38464

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 181659 Collected : 26/Oct/2024 10:52AM Received : 26/Oct/2024 11:35AM

Reported : 26/Oct/2024 04:41PM Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Page 3 of 15







Age/Gender : 31 Y 11 M 2 D/M UHID/MR No : SCHI.0000018366

Visit ID : SCHIOPV38464

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 181659 Collected : 26/Oct/2024 10:52AM
Received : 26/Oct/2024 11:35AM
Reported : 26/Oct/2024 04:41PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method		
BLOOD GROUP ABO AND RH FACTOR, WHOLE BLOOD EDTA						
BLOOD GROUP TYPE	В			Forward & Reverse Grouping with Slide/Tube Aggluti		
Rh TYPE	POSITIVE			Forward & Reverse Grouping with Slide/Tube Agglutination		

Page 4 of 15







Age/Gender : 31 Y 11 M 2 D/M UHID/MR No : SCHI.0000018366

Visit ID : SCHIOPV38464

Ref Doctor : Dr.SELF : 181659 Emp/Auth/TPA ID

Collected : 26/Oct/2024 10:52AM Received : 26/Oct/2024 12:25PM

Reported : 26/Oct/2024 02:48PM

: Final Report Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

Status

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
GLUCOSE, FASTING , NAF PLASMA	89	mg/dL	70-100	GOD - POD

Comment:

As per American Diabetes Guidelines, 2023

Fasting Glucose Values in mg/dL	Interpretation
70-100 mg/dL	Normal
100-125 mg/dL	Prediabetes
≥126 mg/dL	Diabetes
<70 mg/dL	Hypoglycemia

Note:

- 1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions.
- 2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

Page 5 of 15







Age/Gender : 31 Y 11 M 2 D/M UHID/MR No : SCHI.0000018366

Visit ID : SCHIOPV38464

Ref Doctor : Dr.SELF : 181659 Emp/Auth/TPA ID

Collected : 26/Oct/2024 02:37PM Received : 26/Oct/2024 03:20PM

Reported : 26/Oct/2024 07:17PM

: Final Report Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

Status

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
GLUCOSE, POST PRANDIAL (PP), 2 HOURS, SODIUM FLUORIDE PLASMA (2 HR)	101	mg/dL	70-140	GOD - POD

Comment:

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each other.

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

Page 6 of 15









Age/Gender : 31 Y 11 M 2 D/M
UHID/MR No : SCHI.0000018366
Visit ID : SCHIOPV38464

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 181659 Collected : 26/Oct/2024 10:52AM

Received : 26/Oct/2024 04:03PM

Reported : 26/Oct/2024 05:57PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
HBA1C (GLYCATED HEMOGLOBIN),	WHOLE BLOOD EDTA			
HBA1C, GLYCATED HEMOGLOBIN	5.6	%		HPLC
ESTIMATED AVERAGE GLUCOSE (eAG)	114	mg/dL		Calculated

Comment:

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	HBA1C %
NON DIABETIC	<5.7
PREDIABETES	5.7 – 6.4
DIABETES	≥ 6.5
DIABETICS	
EXCELLENT CONTROL	6 – 7
FAIR TO GOOD CONTROL	7 – 8
UNSATISFACTORY CONTROL	8 – 10
POOR CONTROL	>10

Note: Dietary preparation or fasting is not required.

1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic

Control by American Diabetes Association guidelines 2023.

- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control A: HbF >25%
 - B: Homozygous Hemoglobinopathy.
 - (Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Page 7 of 15



Dr Nidhi Sachdev M.B.B.S,MD(Pathology) Consultant Pathologist

SIN No:EDT240093506





Age/Gender : 31 Y 11 M 2 D/M
UHID/MR No : SCHI.0000018366

Visit ID : SCHIOPV38464

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 181659 Collected : 26/Oct/2024 10:52AM
Received : 26/Oct/2024 11:45AM
Reported : 26/Oct/2024 03:43PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
LIPID PROFILE , SERUM		<u>'</u>	1	
TOTAL CHOLESTEROL	168	mg/dL	<200	CHE/CHO/POD
TRIGLYCERIDES	159	mg/dL	<150	Enzymatic
HDL CHOLESTEROL	49	mg/dL	>40	CHE/CHO/POD
NON-HDL CHOLESTEROL	119	mg/dL	<130	Calculated
LDL CHOLESTEROL	87.2	mg/dL	<100	Calculated
VLDL CHOLESTEROL	31.8	mg/dL	<30	Calculated
CHOL / HDL RATIO	3.43		0-4.97	Calculated
ATHEROGENIC INDEX (AIP)	0.15		<0.11	Calculated

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500
LDL	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190
HDL	≥ 60			
NON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220

Page 8 of 15







Age/Gender : 31 Y 11 M 2 D/M UHID/MR No : SCHI.0000018366

Visit ID : SCHIOPV38464

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 181659 Collected : 26/Oct/2024 10:52AM
Received : 26/Oct/2024 11:45AM
Reported : 26/Oct/2024 03:43PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
IVER FUNCTION TEST (LFT) , SERUM		'		<u>'</u>
BILIRUBIN, TOTAL	0.70	mg/dL	0.20-1.30	DIAZO METHOD
BILIRUBIN CONJUGATED (DIRECT)	0.30	mg/dL	0.0-0.3	Calculated
BILIRUBIN (INDIRECT)	0.40	mg/dL	0.0-1.1	Dual Wavelength
ALANINE AMINOTRANSFERASE (ALT/SGPT)	47	U/L	<50	Visible with P-5-P
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	37.0	U/L	17-59	UV with P-5-P
AST (SGOT) / ALT (SGPT) RATIO (DE RITIS)	0.8		<1.15	Calculated
ALKALINE PHOSPHATASE	88.00	U/L	38-126	p-nitrophenyl phosphate
PROTEIN, TOTAL	7.90	g/dL	6.3-8.2	Biuret
ALBUMIN	5.00	g/dL	3.5 - 5	Bromocresol Green
GLOBULIN	2.90	g/dL	2.0-3.5	Calculated
A/G RATIO	1.72		0.9-2.0	Calculated

Comment:

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin) Common patterns seen:

- 1. Hepatocellular Injury:
- *AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.*ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI. Disproportionate increase in AST, ALT compared with ALP. AST: ALT (ratio) In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.
- 2. Cholestatic Pattern:*ALP Disproportionate increase in ALP compared with AST, ALT. ALP elevation also seen in pregnancy, impacted by age and sex.*Bilirubin elevated- predominantly direct , To establish the hepatic origin correlation with elevated GGT helps.
- 3. Synthetic function impairment:*Albumin-Liver disease reduces albumin levels, Correlation with PT (Prothrombin Time) helps.
- 4. Associated tests for assessment of liver fibrosis Fibrosis-4 and APRI Index.

Page 9 of 15







Age/Gender : 31 Y 11 M 2 D/M
UHID/MR No : SCHI.0000018366

Visit ID : SCHIOPV38464

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 181659 Collected : 26/Oct/2024 10:52AM
Received : 26/Oct/2024 11:45AM
Reported : 26/Oct/2024 03:43PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method			
RENAL PROFILE/KIDNEY FUNCTION TEST (RFT/KFT), SERUM							
CREATININE	0.70	mg/dL	0.66-1.25	Creatinine amidohydrolase			
UREA	14.90	mg/dL	19-43	Urease			
BLOOD UREA NITROGEN	7.0	mg/dL	8.0 - 23.0	Calculated			
URIC ACID	6.00	mg/dL	3.5-8.5	Uricase			
CALCIUM	9.80	mg/dL	8.4 - 10.2	Arsenazo-III			
PHOSPHORUS, INORGANIC	3.30	mg/dL	2.5-4.5	PMA Phenol			
SODIUM	137	mmol/L	135-145	Direct ISE			
POTASSIUM	4.4	mmol/L	3.5-5.1	Direct ISE			
CHLORIDE	99	mmol/L	98 - 107	Direct ISE			
PROTEIN, TOTAL	7.90	g/dL	6.3-8.2	Biuret			
ALBUMIN	5.00	g/dL	3.5 - 5	Bromocresol Green			
GLOBULIN	2.90	g/dL	2.0-3.5	Calculated			
A/G RATIO	1.72		0.9-2.0	Calculated			

Page 10 of 15







Age/Gender : 31 Y 11 M 2 D/M UHID/MR No : SCHI.0000018366

Visit ID : SCHIOPV38464

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 181659

Collected : 26/Oct/2024 10:52AM Received : 26/Oct/2024 11:45AM

Reported : 26/Oct/2024 03:43PM

: Final Report Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

Status

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
GAMMA GLUTAMYL TRANSPEPTIDASE (GGT) , SERUM	42.00	U/L	15-73	Glyclyclycine Nitoranalide

Page 11 of 15









Age/Gender : 31 Y 11 M 2 D/M UHID/MR No : SCHI.0000018366

Visit ID : SCHIOPV38464

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 181659 Collected : 26/Oct/2024 10:52AM
Received : 26/Oct/2024 03:57PM
Reported : 26/Oct/2024 05:36PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method		
THYROID PROFILE TOTAL (T3, T4, TSH) , SERUM						
TRI-IODOTHYRONINE (T3, TOTAL)	1.44	ng/mL	0.87-1.78	CLIA		
THYROXINE (T4, TOTAL)	10.07	μg/dL	5.48-14.28	CLIA		
THYROID STIMULATING HORMONE (TSH)	3.048	μIU/mL	0.38-5.33	CLIA		

Comment:

For pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)
First trimester	0.1 - 2.5
Second trimester	0.2 - 3.0
Third trimester	0.3 - 3.0

- **1.** TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- **2.** TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- **3.** Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.
- **4.** Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	T3	T4	FT4	Conditions
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis
High	N	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Treatment.
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy
Low	N	N	N	Subclinical Hyperthyroidism
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism
Low	N	High	High	Thyroiditis, Interfering Antibodies
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes

Page 12 of 15



Dr Nidhi Sachdev M.B.B.S,MD(Pathology) Consultant Pathologist

SIN No:SPL24144955







Age/Gender : 31 Y 11 M 2 D/M UHID/MR No : SCHI.0000018366

Visit ID : SCHIOPV38464

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 181659 Collected : 26/Oct/2024 10:52AM Received : 26/Oct/2024 03:57PM

Received : 26/Oct/2024 03:57PM Reported : 26/Oct/2024 05:36PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma
------	------	------	------	--

Dr Nidhi Sachdev M.B.B.S,MD(Pathology) Consultant Pathologist

SIN No:SPL24144955







Age/Gender : 31 Y 11 M 2 D/M UHID/MR No : SCHI.0000018366

Visit ID : SCHIOPV38464

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 181659 Collected : 26/Oct/2024 10:52AM
Received : 26/Oct/2024 06:38PM
Reported : 26/Oct/2024 07:18PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
COMPLETE URINE EXAMINATION (CUE) , URINE			
PHYSICAL EXAMINATION				
COLOUR	PALE YELLOW		PALE YELLOW	Visual
TRANSPARENCY	CLEAR		CLEAR	Physical Measuremen
рН	6.0		5-7.5	Double Indicator
SP. GRAVITY	1.025		1.002-1.030	Bromothymol Blue
BIOCHEMICAL EXAMINATION				
URINE PROTEIN	NEGATIVE		NEGATIVE	Protein Error Of Indicator
GLUCOSE	NEGATIVE		NEGATIVE	Glucose Oxidase
URINE BILIRUBIN	NEGATIVE		NEGATIVE	Azo Coupling Reaction
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	Sodium Nitro Prusside
UROBILINOGEN	NORMAL		NORMAL	Modifed Ehrlich Reaction
NITRITE	NEGATIVE		NEGATIVE	Diazotization
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	Leucocyte Esterase
CENTRIFUGED SEDIMENT WET M	OUNT AND MICROSCOPY	1		
PUS CELLS	2-4	/hpf	0-5	Microscopy
EPITHELIAL CELLS	2-4	/hpf	<10	Microscopy
RBC	ABSENT	/hpf	0-2	Microscopy
CASTS	ABSENT		0-2 Hyaline Cast	Microscopy
CRYSTALS	ABSENT		ABSENT	Microscopy

Comment:

All urine samples are checked for adequacy and suitability before examination. All abnormal chemical examination are rechecked and verified by manual methods. Microscopy findings are reported as an average of 10 high power fields.

Page 14 of 15







Age/Gender : 31 Y 11 M 2 D/M UHID/MR No : SCHI.0000018366

Visit ID : SCHIOPV38464

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 181659

Collected : 26/Oct/2024 10:52AM Received : 26/Oct/2024 06:38PM

: 26/Oct/2024 07:18PM Reported

: Final Report Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

Status

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
URINE GLUCOSE(POST PRANDIAL)	NEGATIVE		NEGATIVE	GOD-POD
Test Name	Result	Unit	Bio. Ref. Interval	Method
URINE GLUCOSE(FASTING)	NEGATIVE		NEGATIVE	GOD-POD

*** End Of Report ***

Page 15 of 15







Age/Gender : 31 Y 11 M 2 D/M UHID/MR No : SCHI.000001836

UHID/MR No : SCHI.0000018366 Visit ID : SCHIOPV38464

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 181659 Collected : 26/Oct/2024 10:52AM

Received : 26/Oct/2024 06:38PM Reported : 26/Oct/2024 07:18PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

TERMS AND CONDITIONS GOVERNING THIS REPORT

- 1. Reported results are for information and interpretation of the referring doctor or such other medical professionals, who understandreporting units, reference ranges and limitation of technologies. Laboratories not be responsible for any interpretation whatsoever.
- 2. It is presumed that the tests performed are, on the specimen / sample being to the patient named or identified and the verifications of parrticulars have been confirmed by the patient or his / her representative at the point of generation of said specimen.
- 3. The reported results are restricted to the given specimen only. Results may vary from lab to lab and from time to time for the same parameter for the same patient (within subject biological variation).
- 4. The patient details along with their results in certain cases like notifiable diseases and as per local regulatory requirements will be communicated to the assigned regulatory bodies.
- 5. The patient samples can be used as part of internal quality control, test verification, data analysis purposes within the testing scope of the laboratory.
- 6. This report is not valid for medico legal purposes. It is performed to facilitate medical diagnosis only.







Age/Gender : 31 Y 11 M 2 D/M UHID/MR No : SCHI.0000018366

Visit ID : SCHIOPV38464

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 181659 Collected : 26/Oct/2024 10:52AM
Received : 26/Oct/2024 11:35AM
Reported : 26/Oct/2024 04:41PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

PERIPHERAL SMEAR, WHOLE BLOOD EDTA

Page 1 of 15







Age/Gender : 31 Y 11 M 2 D/M UHID/MR No : SCHI.0000018366

Visit ID : SCHIOPV38464

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 181659 Collected : 26/Oct/2024 10:52AM
Received : 26/Oct/2024 11:35AM
Reported : 26/Oct/2024 04:41PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
HEMOGRAM , WHOLE BLOOD EDTA				
HAEMOGLOBIN	13.8	g/dL	13-17	CYANIDE FREE COLOUROMETER
PCV	43.50	%	40-50	PULSE HEIGHT AVERAGE
RBC COUNT	5.37	Million/cu.mm	4.5-5.5	Electrical Impedence
MCV	80.9	fL	83-101	Calculated
MCH	25.6	pg	27-32	Calculated
MCHC	31.7	g/dL	31.5-34.5	Calculated
R.D.W	14.5	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	5,870	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUN	T (DLC)			
NEUTROPHILS	55.3	%	40-80	Electrical Impedance
LYMPHOCYTES	32	%	20-40	Electrical Impedance
EOSINOPHILS	3.9	%	1-6	Electrical Impedance
MONOCYTES	7.9	%	2-10	Electrical Impedance
BASOPHILS	0.9	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT				
NEUTROPHILS	3246.11	Cells/cu.mm	2000-7000	Calculated
LYMPHOCYTES	1878.4	Cells/cu.mm	1000-3000	Calculated
EOSINOPHILS	228.93	Cells/cu.mm	20-500	Calculated
MONOCYTES	463.73	Cells/cu.mm	200-1000	Calculated
BASOPHILS	52.83	Cells/cu.mm	0-100	Calculated
Neutrophil lymphocyte ratio (NLR)	1.73		0.78- 3.53	Calculated
PLATELET COUNT	242000	cells/cu.mm	150000-410000	IMPEDENCE/MICROSCOPY
ERYTHROCYTE SEDIMENTATION RATE (ESR)	10	mm at the end of 1 hour	0-15	Modified Westergren
PERIPHERAL SMEAR				

RBCs ARE NORMOCYTIC NORMOCHROMIC.

TLC , DLC WITHIN NORMAL LIMIT. NO IMMATURE CELLS ARE SEEN. PLATELETS ARE ADEQUATE.

Page 2 of 15







Age/Gender : 31 Y 11 M 2 D/M UHID/MR No : SCHI.0000018366

Visit ID : SCHIOPV38464

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 181659 Collected : 26/Oct/2024 10:52AM Received : 26/Oct/2024 11:35AM

Reported : 26/Oct/2024 04:41PM Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Page 3 of 15







Age/Gender : 31 Y 11 M 2 D/M UHID/MR No : SCHI.0000018366

Visit ID : SCHIOPV38464

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 181659 Collected : 26/Oct/2024 10:52AM
Received : 26/Oct/2024 11:35AM
Reported : 26/Oct/2024 04:41PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method				
BLOOD GROUP ABO AND RH FACTOR	BLOOD GROUP ABO AND RH FACTOR , WHOLE BLOOD EDTA							
BLOOD GROUP TYPE	В			Forward & Reverse Grouping with Slide/Tube Aggluti				
Rh TYPE	POSITIVE			Forward & Reverse Grouping with Slide/Tube Agglutination				

Page 4 of 15







Age/Gender : 31 Y 11 M 2 D/M UHID/MR No : SCHI.0000018366

Visit ID : SCHIOPV38464

Ref Doctor : Dr.SELF : 181659 Emp/Auth/TPA ID

Collected : 26/Oct/2024 10:52AM Received : 26/Oct/2024 12:25PM

Reported : 26/Oct/2024 02:48PM

: Final Report Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

Status

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
GLUCOSE, FASTING , NAF PLASMA	89	mg/dL	70-100	GOD - POD

Comment:

As per American Diabetes Guidelines, 2023

Fasting Glucose Values in mg/dL	Interpretation
70-100 mg/dL	Normal
100-125 mg/dL	Prediabetes
≥126 mg/dL	Diabetes
<70 mg/dL	Hypoglycemia

Note:

- 1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions.
- 2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

Page 5 of 15







Age/Gender : 31 Y 11 M 2 D/M UHID/MR No : SCHI.0000018366

Visit ID : SCHIOPV38464

Ref Doctor : Dr.SELF : 181659 Emp/Auth/TPA ID

Collected : 26/Oct/2024 02:37PM Received : 26/Oct/2024 03:20PM

Reported : 26/Oct/2024 07:17PM

: Final Report Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

Status

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
GLUCOSE, POST PRANDIAL (PP), 2 HOURS, SODIUM FLUORIDE PLASMA (2 HR)	101	mg/dL	70-140	GOD - POD

Comment:

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each other.

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

Page 6 of 15









Age/Gender : 31 Y 11 M 2 D/M
UHID/MR No : SCHI.0000018366
Visit ID : SCHIOPV38464

Ref Doctor : Dr.SELF

Emp/Auth/TPA ID : 181659

Collected : 26/Oct/2024 10:52AM
Received : 26/Oct/2024 04:03PM
Reported : 26/Oct/2024 05:57PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method		
HBA1C (GLYCATED HEMOGLOBIN) , WHOLE BLOOD EDTA						
HBA1C, GLYCATED HEMOGLOBIN	5.6	%		HPLC		
ESTIMATED AVERAGE GLUCOSE (eAG)	114	mg/dL		Calculated		

Comment:

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	HBA1C %		
NON DIABETIC	<5.7		
PREDIABETES	5.7 - 6.4		
DIABETES	≥ 6.5		
DIABETICS			
EXCELLENT CONTROL	6 – 7		
FAIR TO GOOD CONTROL	7 – 8		
UNSATISFACTORY CONTROL	8 – 10		
POOR CONTROL	>10		

Note: Dietary preparation or fasting is not required.


1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic

Control by American Diabetes Association guidelines 2023.

- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control A: HbF >25%
 - B: Homozygous Hemoglobinopathy.
 - (Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Page 7 of 15





SIN No:EDT240093506





Age/Gender : 31 Y 11 M 2 D/M
UHID/MR No : SCHI.0000018366

Visit ID : SCHIOPV38464

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 181659 Collected : 26/Oct/2024 10:52AM
Received : 26/Oct/2024 11:45AM
Reported : 26/Oct/2024 03:43PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method				
LIPID PROFILE, SERUM								
TOTAL CHOLESTEROL	168	mg/dL	<200	CHE/CHO/POD				
TRIGLYCERIDES	159	mg/dL	<150	Enzymatic				
HDL CHOLESTEROL	49	mg/dL	>40	CHE/CHO/POD				
NON-HDL CHOLESTEROL	119	mg/dL	<130	Calculated				
LDL CHOLESTEROL	87.2	mg/dL	<100	Calculated				
VLDL CHOLESTEROL	31.8	mg/dL	<30	Calculated				
CHOL / HDL RATIO	3.43		0-4.97	Calculated				
ATHEROGENIC INDEX (AIP)	0.15		<0.11	Calculated				

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500
LDL	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190
HDL	≥ 60			
NON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220

Page 8 of 15







Age/Gender : 31 Y 11 M 2 D/M UHID/MR No : SCHI.0000018366

Visit ID : SCHIOPV38464

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 181659 Collected : 26/Oct/2024 10:52AM
Received : 26/Oct/2024 11:45AM
Reported : 26/Oct/2024 03:43PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method				
LIVER FUNCTION TEST (LFT), SERUM								
BILIRUBIN, TOTAL	0.70	mg/dL	0.20-1.30	DIAZO METHOD				
BILIRUBIN CONJUGATED (DIRECT)	0.30	mg/dL	0.0-0.3	Calculated				
BILIRUBIN (INDIRECT)	0.40	mg/dL	0.0-1.1	Dual Wavelength				
ALANINE AMINOTRANSFERASE (ALT/SGPT)	47	U/L	<50	Visible with P-5-P				
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	37.0	U/L	17-59	UV with P-5-P				
AST (SGOT) / ALT (SGPT) RATIO (DE RITIS)	0.8		<1.15	Calculated				
ALKALINE PHOSPHATASE	88.00	U/L	38-126	p-nitrophenyl phosphate				
PROTEIN, TOTAL	7.90	g/dL	6.3-8.2	Biuret				
ALBUMIN	5.00	g/dL	3.5 - 5	Bromocresol Green				
GLOBULIN	2.90	g/dL	2.0-3.5	Calculated				
A/G RATIO	1.72		0.9-2.0	Calculated				

Comment:

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin) Common patterns seen:

- 1. Hepatocellular Injury:
- *AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.*ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI. Disproportionate increase in AST, ALT compared with ALP. AST: ALT (ratio) In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.
- 2. Cholestatic Pattern:*ALP Disproportionate increase in ALP compared with AST, ALT. ALP elevation also seen in pregnancy, impacted by age and sex.*Bilirubin elevated- predominantly direct , To establish the hepatic origin correlation with elevated GGT helps.
- 3. Synthetic function impairment:*Albumin-Liver disease reduces albumin levels, Correlation with PT (Prothrombin Time) helps.
- 4. Associated tests for assessment of liver fibrosis Fibrosis-4 and APRI Index.

Page 9 of 15







Age/Gender : 31 Y 11 M 2 D/M
UHID/MR No : SCHI.0000018366

Visit ID : SCHIOPV38464

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 181659 Collected : 26/Oct/2024 10:52AM
Received : 26/Oct/2024 11:45AM
Reported : 26/Oct/2024 03:43PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
RENAL PROFILE/KIDNEY FUNCTION	TEST (RFT/KFT) , SER	RUM	1	
CREATININE	0.70	mg/dL	0.66-1.25	Creatinine amidohydrolase
UREA	14.90	mg/dL	19-43	Urease
BLOOD UREA NITROGEN	7.0	mg/dL	8.0 - 23.0	Calculated
URIC ACID	6.00	mg/dL	3.5-8.5	Uricase
CALCIUM	9.80	mg/dL	8.4 - 10.2	Arsenazo-III
PHOSPHORUS, INORGANIC	3.30	mg/dL	2.5-4.5	PMA Phenol
SODIUM	137	mmol/L	135-145	Direct ISE
POTASSIUM	4.4	mmol/L	3.5-5.1	Direct ISE
CHLORIDE	99	mmol/L	98 - 107	Direct ISE
PROTEIN, TOTAL	7.90	g/dL	6.3-8.2	Biuret
ALBUMIN	5.00	g/dL	3.5 - 5	Bromocresol Green
GLOBULIN	2.90	g/dL	2.0-3.5	Calculated
A/G RATIO	1.72		0.9-2.0	Calculated

Page 10 of 15







Age/Gender : 31 Y 11 M 2 D/M UHID/MR No : SCHI.0000018366

Visit ID : SCHIOPV38464

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 181659 Collected : 26/Oct/2024 10:52AM Received : 26/Oct/2024 11:45AM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

: 26/Oct/2024 03:43PM

DEPARTMENT OF BIOCHEMISTRY

Reported

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
GAMMA GLUTAMYL TRANSPEPTIDASE (GGT), SERUM	42.00	U/L	15-73	Glyclyclycine Nitoranalide

Page 11 of 15









Age/Gender : 31 Y 11 M 2 D/M UHID/MR No : SCHI.0000018366

Visit ID : SCHIOPV38464

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 181659 Collected : 26/Oct/2024 10:52AM
Received : 26/Oct/2024 03:57PM
Reported : 26/Oct/2024 05:36PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method				
THYROID PROFILE TOTAL (T3, T4, TSH), SERUM								
TRI-IODOTHYRONINE (T3, TOTAL)	1.44	ng/mL	0.87-1.78	CLIA				
THYROXINE (T4, TOTAL)	10.07	μg/dL	5.48-14.28	CLIA				
THYROID STIMULATING HORMONE (TSH)	3.048	μIU/mL	0.38-5.33	CLIA				

Comment:

For pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)
First trimester	0.1 - 2.5
Second trimester	0.2 - 3.0
Third trimester	0.3 - 3.0

- **1.** TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- **2.** TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- **3.** Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.
- **4.** Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	T3	T4	FT4	Conditions
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis
High	N	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Treatment.
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy
Low	N	N	N	Subclinical Hyperthyroidism
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism
Low	N	High	High	Thyroiditis, Interfering Antibodies
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes

Page 12 of 15



Dr Nidhi Sachdev M.B.B.S,MD(Pathology) Consultant Pathologist

SIN No:SPL24144955







Age/Gender : 31 Y 11 M 2 D/M UHID/MR No : SCHI.0000018366

Visit ID : SCHIOPV38464

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 181659 Collected : 26/Oct/2024 10:52AM Received : 26/Oct/2024 03:57PM

Received : 26/Oct/2024 03:57PM Reported : 26/Oct/2024 05:36PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma
------	------	------	------	--

Dr Nidhi Sachdev M.B.B.S,MD(Pathology) Consultant Pathologist

SIN No:SPL24144955







Age/Gender : 31 Y 11 M 2 D/M UHID/MR No : SCHI.0000018366

Visit ID : SCHIOPV38464

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 181659 Collected : 26/Oct/2024 10:52AM
Received : 26/Oct/2024 06:38PM
Reported : 26/Oct/2024 07:18PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
COMPLETE URINE EXAMINATION (CUE) , URINE			
PHYSICAL EXAMINATION				
COLOUR	PALE YELLOW		PALE YELLOW	Visual
TRANSPARENCY	CLEAR		CLEAR	Physical Measuremen
рН	6.0		5-7.5	Double Indicator
SP. GRAVITY	1.025		1.002-1.030	Bromothymol Blue
BIOCHEMICAL EXAMINATION				
URINE PROTEIN	NEGATIVE		NEGATIVE	Protein Error Of Indicator
GLUCOSE	NEGATIVE		NEGATIVE	Glucose Oxidase
URINE BILIRUBIN	NEGATIVE		NEGATIVE	Azo Coupling Reaction
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	Sodium Nitro Prusside
UROBILINOGEN	NORMAL		NORMAL	Modifed Ehrlich Reaction
NITRITE	NEGATIVE		NEGATIVE	Diazotization
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	Leucocyte Esterase
CENTRIFUGED SEDIMENT WET M	OUNT AND MICROSCOPY	1		
PUS CELLS	2-4	/hpf	0-5	Microscopy
EPITHELIAL CELLS	2-4	/hpf	<10	Microscopy
RBC	ABSENT	/hpf	0-2	Microscopy
CASTS	ABSENT		0-2 Hyaline Cast	Microscopy
CRYSTALS	ABSENT		ABSENT	Microscopy

Comment:

All urine samples are checked for adequacy and suitability before examination. All abnormal chemical examination are rechecked and verified by manual methods. Microscopy findings are reported as an average of 10 high power fields.

Page 14 of 15







Age/Gender : 31 Y 11 M 2 D/M UHID/MR No : SCHI.0000018366

Visit ID : SCHIOPV38464

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 181659

Collected : 26/Oct/2024 10:52AM Received : 26/Oct/2024 06:38PM

: 26/Oct/2024 07:18PM Reported

: Final Report Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

Status

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
URINE GLUCOSE(POST PRANDIAL)	NEGATIVE		NEGATIVE	GOD-POD
Test Name	Result	Unit	Bio. Ref. Interval	Method
URINE GLUCOSE(FASTING)	NEGATIVE		NEGATIVE	GOD-POD

*** End Of Report ***

Page 15 of 15







Age/Gender : 31 Y 11 M 2 D/M UHID/MR No : SCHI.000001836

UHID/MR No : SCHI.0000018366 Visit ID : SCHIOPV38464

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 181659 Collected : 26/Oct/2024 10:52AM

Received : 26/Oct/2024 06:38PM Reported : 26/Oct/2024 07:18PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

TERMS AND CONDITIONS GOVERNING THIS REPORT

- 1. Reported results are for information and interpretation of the referring doctor or such other medical professionals, who understandreporting units, reference ranges and limitation of technologies. Laboratories not be responsible for any interpretation whatsoever.
- 2. It is presumed that the tests performed are, on the specimen / sample being to the patient named or identified and the verifications of parrticulars have been confirmed by the patient or his / her representative at the point of generation of said specimen.
- 3. The reported results are restricted to the given specimen only. Results may vary from lab to lab and from time to time for the same parameter for the same patient (within subject biological variation).
- 4. The patient details along with their results in certain cases like notifiable diseases and as per local regulatory requirements will be communicated to the assigned regulatory bodies.
- 5. The patient samples can be used as part of internal quality control, test verification, data analysis purposes within the testing scope of the laboratory.
- 6. This report is not valid for medico legal purposes. It is performed to facilitate medical diagnosis only.

